Physician profile
Perry E Trouche
NPI 1932159811
$2,735.17
in general payments reported to CMS, 2019-2025
22 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $686 · 2020: $138 · 2022: $659 · 2023: $820 · 2024: $233 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,251.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $593.31 | 2019-2024 | Rexulti |
| Abbvie INC. | $448.40 | 2022-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $316.72 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $232.49 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $203.47 | 2019-2023 | Spravato |
| Axsome Therapeutics, INC. | $130.33 | 2022-2023 | Auvelity |
| Supernus Pharmaceuticals, INC. | $122.60 | 2022-2023 | Qelbree |
| Vanda Pharmaceuticals INC. | $113.16 | 2022-2024 | Hetlioz, Fanapt |
| Corium, LLC | $112.43 | 2022-2023 | Azstarys |
| Shire North American Group INC | $95.67 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $83.68 | 2023-2024 | Caplyta |
| Idorsia Pharmaceuticals US INC | $54.83 | 2024 | Quviviq |
| Allergan, INC. | $49.54 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $42.66 | 2022 | |
| Tris Pharma INC | $23.74 | 2023 | Dyanavel Xr |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $21.08 | 2025 | Lybalvi |
| Owp Pharmaceuticals, INC. | $18.16 | 2019 | |
| Sunovion Pharmaceuticals INC. | $16.90 | 2019 | |
| Jazz Pharmaceuticals INC. | $16.07 | 2020 | |
| Ironshore Pharmaceuticals INC. | $15.49 | 2019 | |
| Neuronetics, INC. | $12.42 | 2019 | |
| Bausch Health US, LLC | $12.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Perry Trouche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.